Fairholme Focused Income Fund's PFE Position Overview
Fairholme Focused Income Fund (via Fairholme Capital Management LLC) currently holds 231,000 shares of Pfizer Inc. (PFE) worth $5.56 M, representing 0.37% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Fairholme Focused Income Fund has initiated a new position in PFE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Fairholme Focused Income Fund's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Fairholme Focused Income Fund
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +231,000 | New Buy | 231,000 | $24.08 |
Fairholme Focused Income Fund's Pfizer Investment FAQs
Fairholme Focused Income Fund first purchased Pfizer Inc. (PFE) in Q2 2026, acquiring 231,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Fairholme Focused Income Fund has held Pfizer Inc. (PFE) for 1 quarters since Q2 2026.
Fairholme Focused Income Fund's largest addition to Pfizer Inc. (PFE) was in Q2 2026, adding 231,000 shares worth $5.56 M.
According to the latest 13F filing for Q2 2026, Fairholme Focused Income Fund's firm, Fairholme Capital Management LLC, owns 231,000 shares of Pfizer Inc. (PFE), valued at approximately $5.56 M.
As of the Q2 2026 filing, Pfizer Inc. (PFE) represents approximately 0.37% of Fairholme Focused Income Fund's publicly disclosed stock portfolio, making it one of their key holdings.
Fairholme Focused Income Fund's peak holding in Pfizer Inc. (PFE) was 231,000 shares, as reported at the end of Q2 2026.